GlassScriptPhysician profile
Rachel E Rice
NPI 1720559479
$10,798.44
in general payments reported to CMS, 2019-2025
28 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,448 · 2022: $2,142 · 2023: $2,590 · 2024: $1,915 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,034 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,033.95 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,165.85 | 2021-2025 | |
| Amgen INC. | $1,554.89 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,361.17 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,072.99 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $770.89 | 2022-2025 | |
| Glaxosmithkline, LLC. | $556.54 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $379.54 | 2021-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $355.33 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $221.75 | 2021-2025 | Saphnelo |
| Pfizer INC. | $203.39 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $164.30 | 2021-2024 | Acthar |
| Sobi, INC | $127.03 | 2022-2024 | |
| Radius Health, INC. | $118.10 | 2021-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $115.86 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.34 | 2022-2023 | Ofev, Cyltezo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $81.53 | 2022-2025 | Strensiq, Ultomiris |
| Genzyme Corporation | $62.50 | 2021-2025 | |
| Organon LLC | $57.11 | 2025 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $55.22 | 2023-2024 | Lupkynis |
| Kiniksa Pharmaceuticals, LTD. | $53.15 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $51.39 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $41.29 | 2024-2025 | |
| Horizon Therapeutics Plc | $23.98 | 2022 | |
| Sandoz INC. | $20.37 | 2025 | Hyrimoz |
| Mylan Institutional INC. | $19.78 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $19.15 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.29 | 2024 | Horizant |
| Fidia Pharma USA INC. | $15.71 | 2024 | Hyalgan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.